Presentation is loading. Please wait.

Presentation is loading. Please wait.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes  Yayi He, MD, PhD, Hui.

Published byTimo-Pekka Sala Modified over 5 years ago

Similar presentations

Presentation on theme: "LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes  Yayi He, MD, PhD, Hui."— Presentation transcript:

1 LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes  Yayi He, MD, PhD, Hui Yu, PhD, Leslie Rozeboom, BA, Christopher J. Rivard, PhD, Kim Ellison, BA, Rafal Dziadziuszko, MD, PhD, Kenichi Suda, MD, PhD, Shengxiang Ren, MD, PhD, Chunyan Wu, MD, PhD, Likun Hou, MD, PhD, Caicun Zhou, MD, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Lymphocyte activating 3 (LAG-3)-negative expression on an NSCLC cell line (H520) (×20) and positive immunochemistry (IHC) staining for LAG-3, programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1) (×20). (A) LAG-3–negative expression on an NSCLC cell line (H520) (×20). (B) IHC positivity for LAG-3 on tumor-infiltrating lymphocytes (TILs). (C) IHC positivity for PD-1 on tumor-infiltrating lymphocytes (TILs). (D) IHC positivity for PD-L1 on a tumor cell. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Lymphocyte activating 3 (LAG-3) and programmed death ligand 1 (PD-L1) and recurrence-free survival (RFS) and overall survival (OS) in patients with NSCLC. (A) RFS and LAG-3. (B) OS and LAG-3. (C) RFS by PD-L1 and LAG-3. (D) OS by PD-L1 and LAG-3. Abbreviation: Cum, cumulative. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes  Yayi He, MD, PhD, Hui."

Similar presentations

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing  Klazien Matter-Walstra, PhD, Matthias.
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer  Shinjiro.
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer  Chao Li, MD, PhD,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation 

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation 
Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li,

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer  Xiaomei Gong, MD, PhD, Xuefei Li,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer  Hui Yu, MD, PhD, Cory Batenchuk, PhD,
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Similar presentations

Ads by Google